Standard BioTools Inc (LAB) concluded trading on Thursday at a closing price of $1.73, with 3.44 million shares of worth about $5.95 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -25.43% during that period and on January 16, 2025 the price saw a loss of about -14.36%. Currently the company’s common shares owned by public are about 372.26M shares, out of which, 360.48M shares are available for trading.
Stock saw a price change of -1.14% in past 5 days and over the past one month there was a price change of -9.42%. Year-to-date (YTD), LAB shares are showing a performance of -1.14% which decreased to -26.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.21 but also hit the highest price of $3.04 during that period. The average intraday trading volume for Standard BioTools Inc shares is 1.90 million. The stock is currently trading -7.54% below its 20-day simple moving average (SMA20), while that difference is down -7.50% for SMA50 and it goes to -16.45% lower than SMA200.
Standard BioTools Inc (NASDAQ: LAB) currently have 372.26M outstanding shares and institutions hold larger chunk of about 75.18% of that.
The stock has a current market capitalization of $644.01M and its 3Y-monthly beta is at 1.58. It has posted earnings per share of -$0.71 in the same period. It has Quick Ratio of 3.41 while making debt-to-equity ratio of 0.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LAB, volatility over the week remained 13.89% while standing at 8.97% over the month.
Stock’s fiscal year EPS is expected to rise by 62.06% while it is estimated to increase by 43.93% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by TD Cowen on April 16, 2024 offering a Buy rating for the stock and assigned a target price of $3.50 to it. Coverage by Jefferies stated Standard BioTools Inc (LAB) stock as a Buy in their note to investors on April 04, 2024, suggesting a price target of $3.25 for the stock.
